Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Video case report

Colorectal surgery obesity-related morbidity during COVID-19
Lisandro Montorfano, M.D.\textsuperscript{a}, Rafael Miret, M.D.\textsuperscript{a}, Asad Ur Rahman, M.D.\textsuperscript{b}, Mileydis Alonso, M.D.\textsuperscript{a}, David J. Maron, M.D.\textsuperscript{c}, Mayank Roy, M.D.\textsuperscript{a}, Francisco Ferri, M.D.\textsuperscript{a}, Pablo Bejarano\textsuperscript{d}, Steven D. Wexner, M.D., Ph.D. (Hon)\textsuperscript{c,*}

\textsuperscript{a}Department of General Surgery, Cleveland Clinic Florida, Weston, Florida
\textsuperscript{b}Department of Gastroenterology, Cleveland Clinic Florida, Weston, Florida
\textsuperscript{c}Department of Colorectal Surgery, Cleveland Clinic Florida, Weston, Florida
\textsuperscript{d}Department of Laboratory Medicine, Cleveland Clinic Florida, Weston, Florida

Received 28 May 2020; accepted 5 June 2020

Abstract

Tocilizumab, a monoclonal antiinterleukin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus disease 2019 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event. (Surg Obes Relat Dis 2020;16:1372–1375.) © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Key words: COVID-19; SARS-CoV-2 coronavirus; Tocilizumab; IL-6; Corticosteroids; Bowel perforation; Colonic perforation

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) crisis is considered the pandemic of the century [1]. The disease has rapidly spread around the world and has been acknowledged as an international public health emergency because of a lack of sufficient resources to care for the increasing number of patients with acute respiratory distress syndrome due to COVID-19 [2]. Infected patients may present as asymptomatic carriers or may develop symptoms ranging from mild upper respiratory symptoms to signs and symptoms of multiorgan failure [3]. The SARS-CoV-2 coronavirus produces a profound inflammatory state in the human body with marked elevation of serum cytokines, especially interferon gamma, tumor necrosis factor alpha, interleukin (IL)-17, IL-8, and IL-6, which can lead to respiratory failure requiring mechanical ventilation, disseminated intravascular coagulation, and multiorgan failure [4]. Thus far, no curative therapy or protective vaccines are available. Empiric pharmacologic treatments have been used with mixed results, including Hydroxychloroquine, Remdesivir, and Tocilizumab [5–7]. These medications are associated with deleterious adverse effects but because of the lack of viable treatments, physicians have used them around the world in an attempt to improve survival in critically ill patients with COVID-19. The efficacy and safety of these medications for these patients is unknown.

The purpose of this case report was to analyze the risks of acute large bowel perforation after using Tocilizumab empirically for COVID-19 pneumonia in morbidly obese patients and discuss the appropriate management of this adverse event.
Case report

We present the case of a 54-year-old obese female with a past medical history of hypertension who was brought by Emergency Medical Service to the hospital because of progressive decline in mental status in the context of high-grade fever, dyspnea, orthopnea, nonproductive cough, and fatigue over the previous 5 days. Upon arrival to the hospital, the patient was febrile up to 103.3°F, tachycardic, tachypneic, with oxygen saturation of 92% on a nonrebreather mask. Rapid COVID-19 testing using polymerase chain reaction returned positive. Other laboratory workup was significant for C-reactive protein of 22.8 mg/L and N-terminal prohormone of brain natriuretic peptide (NT-Pro BNP) of 567 pg/mL. Chest X-ray showed multifocal airspace infiltrates suspicious for multifocal pneumonia with small pleural effusions (Fig. 1). Arterial blood gas showed pH of 7.49, carbon dioxide level of 38 mm Hg, and arterial oxygen of 69 mm Hg. Due to progressive respiratory insufficiency, the patient was intubated and was empirically treated with Levofloxacin 500 mg and Ceftriaxone 1 g for presumed superimposed pneumonia. Additionally, she also received Hydroxychloroquine 200 mg twice daily for 5 days. Because of persistent hypoxemic respiratory failure, she was treated for 4 days with pronation, paralysis, and inhaled epoprostenol. However, the patient did not show signs of improvement. She was subsequently started on veno-venous extracorporeal membrane oxygenation (ECMO) treatment for 21 days. During this time, the antibiotic spectrum was broadened to cover for hospital-associated pneumonia and she additionally received empiric Tocilizumab 400 mg intravenously. As a result of the persistent need for ventilatory support, the patient underwent tracheostomy and was subsequently decannulated from veno-venous ECMO after showing steady improvement in her respiratory status. Before decannulation, the patient had episodes of epistaxis related to ECMO anticoagulation, which required nasal packing. Because of concerns of localized swelling of the tongue and pharyngeal edema, she also received intravenous 2-mg Dexamethasone. One day after decannulation, the patient had bright red bleeding per rectum and developed tachycardia and hypotension requiring vasopressor support. Chest X-ray showed free air under the right hemidiaphragm (Fig. 2), thereby raising concern for presumed bowel perforation. Despite being high risk, in view of her age and recent recovery from ECMO, the decision was made to take her to the operating room after discussion with a multidisciplinary team and the family members. Intraoperatively, 2 L of fecal material was found in the intra-peritoneal cavity. The abdominal cavity was washed with 10 L of fluids, including all 4 quadrants. The cecum was found to be ischemic and perforated. The stomach and duodenum appeared healthy. The small bowel was run from the jejunum to the terminal ileum with no signs of ischemia. Because of her tenuous status and significant intraabdominal sepsis, she underwent right hemicolectomy with end ileostomy and Hartmann closure of the colon. Histopathologically, the tissue demonstrated transmural coagulative necrosis involving the cecum and extensive fibrinopurulent serositis (Fig. 3). There was no malignancy in the specimen. Postoperatively, the patient received antibiotics and vasopressors for septic shock. The patient demonstrated progressive improvement in her respiratory status and hemodynamics, was weaned off vasopressors, and discharged to a long-term acute care facility.

Discussion

COVID-19 has rapidly spread around the world. Over the last few months, there have been numerous publications in the literature that describe the devastating clinical effects
was shown that the concomitant use of Tocilizumab and on abdominal imaging. In another retrospective study, it
Interestingly, our patient did not have diverticulosis seen
ment of bowel perforation in patients taking Tocilizumab.

46%. The pathophysiology is not completely understood;
mortality rate among patients with bowel perforation was

Strangfeld et al. [14] reported a significant increased risk
the increased risk of lower gastrointestinal perforations.

Tocilizumab in patients with rheumatologic conditions is

safety and efficacy are still under debate.

certain patients with hyperinflammatory phenotype, its
mechanical ventilation, and intensive care unit variables
ary endpoints of the study include clinical status, mortality,
with placebo plus standard of care. The primary and second-
interrelationship of several factors, such as inflammatory
cells, activation of proinflammatory cytokine cascade, inter-

COVID-19–positive patients may require vasoactive medi-
cation therapy caused by the virus. The measurement of D-dimer
levels has proven to be useful in predicting the risk of throm-
bosis and mortality in this patient population, as recently
suggested by a study conducted in Wuhan [19]. An observa-
tional study that included 184 COVID-19–positive cases
showed a 31% incidence of thrombotic events. Anticoagula-
tion in these patients helped prevent the thrombotic effects
of this virus. None of the patients observed in this study
were diagnosed with disseminated intravascular coagula-
tion. Pulmonary embolism was the most frequent throm-
botic complication (n = 5, 81%) [20]. There is growing
evidence that many of the complications and deaths are
related to thrombotic events in critically ill COVID-19–pos-
itive patients. Most physicians are now using prophylactic
anticoagulation medications to treat patients infected with
COVID-19 [21,22]. Currently, there are no reports of bowel ischemia or perforation caused by thrombotic events; how-
ever, this may be a contributing factor for acute large bowel
perforation in COVID-19–positive patients treated empiri-
cally with Tocilizumab.

Additionally, hemodynamically unstable critically ill
COVID-19–positive patients may require vasoactive medi-
cation, potentially leading to intestinal hypoperfusion and
intestinal ischemia. The pathogenesis is believed to be an
interrelationship of several factors, such as inflammatory
cells, activation of proinflammatory cytokine cascade, inter-
ruption of microcirculatory blood flow, as well as the func-
tional integrity of the intestinal mucosa [23]. Intestinal
hypoperfusion may have been a contributing factor; howev-
er, it is unlikely to be the main etiology of large bowel perfo-
ration in the case described herein, because there was no

of this virus [8–11]. However, to the best of our knowledge,
this is the first report describing bowel perforation in a
critically ill COVID-19–positive patient receiving empiric
Tocilizumab. New therapeutic approaches are being
developed to treat critically ill COVID-19–positive patients and rely on controlling the proinflammatory
cytokines, mainly IL-6, IL-10, and tumor necrosis factor-
z. Tocilizumab, a monoclonal antiIL-6 receptor antibody
primarily used for rheumatologic conditions, has been
used in the management of cytokine release syndrome asso-
ciated with severe COVID-19 infection [12]. A randomized,
double-blind, placebo-controlled phase III clinical trial is
currently underway to evaluate the safety and efficacy of
tocilizumab plus standard of care in hospitalized patients
with severe SARS-CoV-2 coronavirus pneumonia compared
with placebo plus standard of care. The primary and second-
ary endpoints of the study include clinical status, mortality,
mechanical ventilation, and intensive care unit variables
[13]. Although promising in controlling the disease in
certain patients with hyperinflammatory phenotype, its
safety and efficacy are still under debate.

One of the most commonly reported complications of
Tocilizumab in patients with rheumatologic conditions is
the increased risk of lower gastrointestinal perforations.
Strangfeld et al. [14] reported a significant increased risk
of bowel perforations in patients using Tocilizumab (2.7
events per 1000 person-years) when they compared them
with patients taking other biological agents. The 30-day
mortality rate among patients with bowel perforation was
46%. The pathophysiology is not completely understood;
however, prior diverticulitis is a risk factor for the develop-
ment of bowel perforation in patients taking Tocilizumab.
Interestingly, our patient did not have diverticulosis seen
on abdominal imaging. In another retrospective study, it
was shown that the concomitant use of Tocilizumab and
Prednisone causes a higher incidence of lower gastrointes-
tinal perforations in comparison to other tumor necrosis

alpha inhibitors [15]. Our patient received both medications
before the acute large bowel perforation occurred, because
she received empiric Tocilizumab for COVID-19 pneumonia and Dexamethasone for several days for pharyngeal
edema.

It has been established that COVID-19 infects the human
organism by binding the angiotensin-converting enzyme
receptors, similar to the mechanism previously described with the SARS pathogen [16]. Angiotensin-converting enzyme
receptors are not only highly expressed in the airway and
lung tissue but also present in the gastrointestinal tract. Viral
nucleic acids have been found in the stool and saliva of
COVID-19–positive patients [17]. These findings support
the possibility that this virus could spread through fecal
oral transmission. A recent study showed that in patients
who manifested with gastrointestinal complaints, the virus
was isolated from fecal material in early stages of the infec-
tion [18]. More research is needed to determine if the im-
mune response to the virus could be a cause of
gastrointestinal perforations.

Another emerging theory for many of the complications
noted in critically ill COVID-19 patients is the hypercoagu-
lable state caused by the virus. The measurement of D-dimer
levels has proven to be useful in predicting the risk of throm-
bosis and mortality in this patient population, as recently
suggested by a study conducted in Wuhan [19]. An observa-
tional study that included 184 COVID-19–positive cases
showed a 31% incidence of thrombotic events. Anticoagula-
tion in these patients helped prevent the thrombotic effects
of this virus. None of the patients observed in this study
were diagnosed with disseminated intravascular coagula-
tion. Pulmonary embolism was the most frequent throm-
botic complication (n = 5, 81%) [20]. There is growing
evidence that many of the complications and deaths are
related to thrombotic events in critically ill COVID-19–pos-
itive patients. Most physicians are now using prophylactic
anticoagulation medications to treat patients infected with
COVID-19 [21,22]. Currently, there are no reports of bowel ischemia or perforation caused by thrombotic events; howev-
er, this may be a contributing factor for acute large bowel
perforation in COVID-19–positive patients treated empiri-
cally with Tocilizumab.

Additionally, hemodynamically unstable critically ill
COVID-19–positive patients may require vasoactive medi-
cation, potentially leading to intestinal hypoperfusion and
intestinal ischemia. The pathogenesis is believed to be an
interrelationship of several factors, such as inflammatory
cells, activation of proinflammatory cytokine cascade, inter-
ruption of microcirculatory blood flow, as well as the func-
tional integrity of the intestinal mucosa [23]. Intestinal
hypoperfusion may have been a contributing factor; howev-
er, it is unlikely to be the main etiology of large bowel perfo-
ration in the case described herein, because there was no

Fig. 3. Transmural coagulative necrosis involving the cecum and extensive fibrinopurulent serositis.
evidence of ischemia in other areas of the small or large intestine supplied by the superior mesenteric artery.

Conclusion

This case report describes a rare case of colonic perforation in a critically ill, morbidly obese patient with COVID-19 pneumonia on empiric Tocilizumab therapy. This report adds data to the currently small body of literature for this finding. It emphasizes the importance of close monitoring for gastrointestinal events in patients infected with COVID-19 receiving Tocilizumab empirically. Further studies are needed to better understand the safety and efficacy of tocilizumab plus standard of care in hospitalized patients with severe COVID-19 infection.

Disclosures

The authors have no commercial associations that might be a conflict of interest in relation to this article.

References

[1] Chakraborty I, Maity P. COVID-19 outbreak: migration, effects on society, global environment and prevention. Sci Total Environ 2020;728:138882.
[2] Prescott K, Baxter E, Lynch C, Jassal S, Bashir A, Gray J. COVID-19: how prepared are front line healthcare workers in England? J Hosp Infect 2020;105(2):142–5.
[3] Al-Balas M, Al-Balas HI, Al-Balas H. Surgery during the COVID-19 pandemic: a comprehensive overview and perioperative care. Am J Surg 2020;219(6):903–6.
[4] Arnaldez FI, O’Day SJ, Drake GG, et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer 2020;8(1):e000930.
[5] Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. Epub 2020 May 11.
[6] Li Z, Wang X, Cao D, Sun S, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther 2020;14(2):73–6.
[7] Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. Epub 2020 May 6.
[8] Wexner SD, Cortés-Guiral D, Gilshtein H, Kent I, Reymond M. COVID-19: impact on colorectal surgery. Colorectal Dis 2020;22(6):635–40.
[9] Tam CF, Cheung KS, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes 2020;13(4):e006631.
[10] Torales J, O’Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry 2020;66(4):317361–420.
[11] Markus HS, Brainin M. COVID-19 and stroke—a global World Stroke Organization perspective. Int J Stroke 2020;15(4):361–4.
[12] Zhong C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6 R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;55(5):105954.
[13] Genentech initiates phase II clinical trial of actemra in hospitalized patients with severe COVID-19 in pneumonia [homepage on the Internet]. San Francisco: Genentech; c2020 [updated 2020 Mar 18; cited 2020 Mar 19]. Available from: https://www.gene.com/media/press-releases/14841/2020-03-18/genentech-initiates-phase-ii-clinical-t.
[14] Strangfeld A, Richter A, Siegmond B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 2017;76(3):504–10.
[15] Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 2016;68(11):2612–7.
[16] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565–74.
[17] Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 2020;158(6):1518–9.
[18] Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. Epub 2020 Jan 31.
[19] Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with covid-19. J Thromb Haemost 2020;18(6):1324–9.
[20] Klofkorn FA, Kruij MJA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.
[21] Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75(23):2950–73.
[22] Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. Epub 2020 Apr 30.